Joseph Pearlberg, M.D., Ph.D.

Joseph Pearlberg, M.D., Ph.D., is the Vice President of Scientific Affairs on the Biotherapeutics group at Deerfield and joined the Firm in 2017. Prior to Deerfield, Dr. Pearlberg was the Vice President of Clinical Development at Infinity Pharmaceuticals. Before Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his Ph.D. in Molecular Biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He holds a B.A. in Biochemistry from the University of Pennsylvania.

Cameron Wheeler, Ph.D.

Cameron Wheeler, Ph.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2014. Prior to Deerfield, Dr. Wheeler worked for and on behalf of Eleven Biotherapeutics, Inc. as a director since 2009. Previous to that, Dr. Wheeler was Manager of the Business Development and Operations team at Constellation Pharmaceuticals, Inc. and a Senior Associate at Third Rock Ventures, LLC. Dr. Wheeler holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.

Howard Furst, M.D.

Howie Furst, M.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2007. Dr. Furst is a physician with eleven years of clinical experience. Prior to Deerfield, Dr. Furst was Portfolio Manager at Magnetar Capital and was responsible for building the firm’s healthcare team and developing its private and public investment approach. Before joining Magnetar, Dr. Furst served as a life sciences analyst at Maverick Capital. Dr. Furst received his B.A. with honors from the University of Pennsylvania, M.D. from New York University and M.B.A. from the Wharton School of the University of Pennsylvania.

Jonathan Leff

Jonathan Leff is a Partner on the Biotherapeutics team at Deerfield and Chairman of the Deerfield Institute and joined the Firm in 2013. Mr. Leff focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to Deerfield, for more than 16 years, Mr. Leff was with Warburg Pincus, where he held the position of Managing Director from 2000 to 2012 and led the firm’s investment efforts in biotechnology and pharmaceuticals. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA), and led NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA-MedIC). He also served on the Emerging Companies Section Board of the Biotechnology Industry Organization. Mr. Leff is a Board member of several not-for-profit organizations, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, Reagan-Udall Foundation and the Columbia University Medical Center Board of Advisors. Mr. Leff received his A.B. from Harvard University, and earned his M.B.A. from the Stanford University Graduate School of Business.

Nicholas Bishop, Ph.D.

Nicholas Bishop, Ph.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2014. He provides extensive research and analysis on individual companies operating in the healthcare industry. Prior to Deerfield, Dr. Bishop spent four years as a research analyst covering the Biotechnology sector at Cowen and Company, where he was recognized as a Rising Star by Institutional Investor in 2013. Prior to entering the finance industry, Dr. Bishop was a biomedical research scientist at Harvard University and Massachusetts Institute of Technology. He has authored several scientific journal articles on the genetic regulation of aging and lifespan, one of which was featured as the cover story for an issue of Nature. Dr. Bishop received his B.A. with honors from Rice University and Ph.D. from the Massachusetts Institute of Technology.

William Slattery

William Slattery is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for ten years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.

Angela Asencio

Angela Asencio is Manager, Therapeutics team at Deerfield and joined the Firm in 2015. Prior to Deerfield, Ms. Asencio worked as an Executive Assistant for five years supporting the High Yield Credit Research team at Barclays. Before that, she supported the President/CEO of AmeriFactors Financial Group for four years. Ms. Asencio also worked at North Eastern Asset Recovery for eight years holding various positions, her last being a Client Relations Manager. She holds a B.A. in Economics from The State University of New York at Albany.

Crystal Wright

Crystal Wright is an Associate on the Biotherapeutics team and joined Deerfield in 2013. Before Deerfield, Ms. Wright was an Executive Assistant at Warburg Pincus and provided support within the firm’s Healthcare Group since 2002. Prior to this, she was an Executive Assistant at various firms, including Deutsche Banc Alex. Brown and the law offices of Cooper, Liebowitz, Royster & Wright where she served as Executive Assistant/Office Manager. Ms. Wright also served as Administrative Assistant/Interim Residency Program Coordinator in the Department of Neurosurgery at Georgetown University Hospital. Ms. Wright is a graduate of Howard University in Washington, DC with a B.S. in Biology.

Veranika Razhkova

Veranika Razhkova is an Analyst on the Biotherapeutics team at Deerfield and joined the Firm in 2015 as a Fellow. She provides extensive research and analysis on early-stage investments. Prior to joining the Biotherapeutics group, Ms. Razhkova worked on patient forecasting in the Deerfield Institute. She holds a B.A. in Natural Sciences from The City University of New York’s Baruch College and M.S. in Biotechnology from Johns Hopkins University.

Zheng Su, Ph.D.

Zheng Su, Ph.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2013. Prior to Deerfield, Dr. Su was a Senior Statistical Scientist at Genentech, an Assistant Professor at SUNY Stony Brook, and a Visiting Assistant Professor at Stanford University. He formerly served as Editor-in-Chief of Contemporary Clinical Trials and Co-Editor-in-Chief of Contemporary Clinical Trials Communications. Dr. Su holds a B.S. in Mathematics from Peking University, and an M.S. in Financial Mathematics and a Ph.D. in Computational Mathematics and Statistics from Stanford University, where he also received his post-doctoral training in biostatistics. He has published over 50 articles on the design and analysis of clinical trials.